Hypomethylating agents as preferred therapy for higher-risk CMML patients

A research team lead by CCS member Lisa Pleyer (image) and CCS director Richard Greil published data of a retrospective cohort study in The Lancet Haematology. The data suggest hypomethylating agents as the preferred therapy for patients with higher-risk chronic myelomonocytic leukaemia and those with myeloproliferative CMML.

Read the entire article here.